The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report
Joshua P Kesterson, Paulette Mhawech-Fauceglia, Shashikant Lele, Joshua P Kesterson, Paulette Mhawech-Fauceglia, Shashikant Lele
Abstract
Background: The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated.
Case: An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.
Conclusion: Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.
Conflict of interest statement
statement The authors have no conflicts of interest to declare.
Figures
Source: PubMed